Phase 4 Kidney Cancer Trial, Recruiting NCT06293677 Sponsor: Centre Hospitalier Universitaire Vaudois Condition: Kidney Cancer
Back to Kidney Cancer

Phase 4 Kidney Cancer Trial, Recruiting

NCT06293677
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your child is between 2 months old and 17 years old and has cancer
  • Your child is likely to develop a fever with a very low white blood cell count (which can happen during cancer treatment) at some point during the study
  • Parents must be willing to give written permission for their child to take part, and teenagers aged 14 and older must also give their own written agreement
  • Your child has a fever (temperature of 38°C or higher lasting at least one hour, or a single reading of 38.5°C or higher) along with a dangerously low level of infection-fighting white blood cells, or is expected to reach that low level within the next 24 hours due to ongoing chemotherapy
  • If your child had a previous episode in this study that was treated with antibiotics, at least 2 weeks must have passed since that antibiotic treatment ended

Who may not be able to join:

  • Your child's low white blood cell count is not caused by cancer or chemotherapy
  • The family or patient does not wish to take part
  • The parents, or patients older than 11 years, do not speak French
  • Your child does not experience a fever with very low white blood cells during the study period (this would be confirmed after joining)
  • Your child has very severe kidney problems (confirm with trial site)
  • Your child is pregnant
  • It is not possible to get a blood medication level result back within 72 hours of taking the sample — for example, if admission happens just before a public holiday when the lab is closed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Pierre-Alex Crisinel, Centre Hospitalier Universitaire Vaudois

Phone: +41(0)795563598

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Centre Hospitalier Universitaire Vaudois
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
1 March 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Achievement of antibiotic concentration targets in the intervention group (1i) vs control groupe (1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov